Ani pharmaceuticals announces the fda approval and launch of levocarnitine tablets usp

Baudette, minn.--( business wire )--ani pharmaceuticals, inc. (ani or the company) (nasdaq: anip) today announced that it received u.s. food and drug administration (fda) approval for the abbreviated new drug application (anda) for levocarnitine tablets usp, 330 mg.

ANIP Ratings Summary

ANIP Quant Ranking